<DOC>
	<DOCNO>NCT02782312</DOCNO>
	<brief_summary>The objective study assess efficacy safety Salmeterol-Fluticasone （ICS LABA）combined inhaled therapy non-cystic fibrosis（non-CF）bronchiectasis patient chronic airflow obstruction . Moreover , subgroup analysis perform explore population bronchiectasis patient treatment suitable .</brief_summary>
	<brief_title>Salmeterol-Fluticasone Combined Inhaled Therapy Non-cystic Fibrosis Bronchiectasis</brief_title>
	<detailed_description>Inhaled ICS LABA prove obvious benefit asthma chronic obstructive pulmonary disease ( COPD ) patient . However , presently clear evidence effect ICS LABA combine inhaled therapy non-CF bronchiectasis patient . This study design prospective , randomized , control trial . Patients divide two group , one group inhale ICS LABA ( Seretide ) , another group receive routine therapy ( oxygen uptake , phlegm dissipation , hemostasis postural drainage naturopathy ) .The course treatment 12 month . All patient underwent review baseline entry study month 6 12 treatment . The quality life ( QOL ) scores：St George 's dyspnea score ( SGRQ score） , modify british medical reserach council（mMRC score ) COPD assessment test ( CAT score ) ; lung function test : forced expiratory volume one second ( FEV1） , FEV1 % predict , ratio force expiratory volume one second force vital capacity ( FEV1/FVC % ) ; short-acting β2-adrenergic agonist（SABA）use incidence adverse event monitor throughout study .</detailed_description>
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Fluticasone Propionate , Salmeterol Xinafoate Drug Combination</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>stable bronchiectasis ; ability complete pulmonary function test ; FEV1/FVC &lt; 70 % ; ≥2 exacerbation within past year cigarette smoke history 10 packyears ; cystic fibrosis traction bronchiectasis due various pulmonary fibrosis ; active pulmonary mycobacterial infection ; fungal infection ; active sarcoidosis ; active allergic bronchopulmonary aspergillosis ( ABPA ) ; asthma define Global Initiative Asthma ( GINA ) ; patient severe cardiopulmonary dysfunction ; impair hepatic kidney function ; hypogammaglobulinemia autoimmune disease ; pregnant breastfeeding woman ; patient know intolerance ICS LABAs .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Bronchiectasis</keyword>
	<keyword>ICS+LABA</keyword>
</DOC>